Related Experiment Video
Updated: Jun 5, 2026

Identification of Functional Protein Regions Through Chimeric Protein Construction
Published on: January 8, 2019
A receptor fusion protein for the inhibition of murine oncostatin M
Liv Brolund1, Andrea Küster, Sabrina Korr
1Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Aachen, Germany.
Background:
Most cytokines signal through heteromeric receptor complexes consisting of two or more different receptor subunits. Fusion proteins of the extracellular parts of receptor subunits turned out to be promising cytokine inhibitors useful in anti-cytokine therapy and cytokine research.
Results:
We constructed receptor fusion proteins (RFP) consisting of the ligand binding domains of the murine oncostatin M (mOSM) receptor subunits mOSMR and mgp130 connected by a flexible linker as potential mOSM inhibitors. mgp130 is a shared cytokine receptor that is also used by other cytokines such as IL-6 and leukemia inhibitory factor (LIF). In this study we compare four types of mOSM-RFPs that contain either domains D1-D3 or domains D2-D3 of mgp130 and are arranged in two ways. Domain D1 of mgp130 turned out to be dispensable for mOSM-binding. However, the arrangement of the two receptor subunits is essential for the inhibitory activity. We found mOSM induced STAT3 phosphorylation to be suppressed only when the mOSMR fragment was fused in front of the mgp130 fragment.
Conclusions:
mOSM-RFP consisting of D1-D4 of mOSMR and D2-D3 of mgp130 is a highly potent and specific inhibitor of mOSM. Since mOSM-RFP is encoded by a single gene it offers numerous possibilities for specific cytokine inhibition in gene delivery approaches based on viral vectors, transgenic animals and finally gene therapy.
Insights
Researchers developed a potent fusion protein inhibitor for murine oncostatin M (mOSM). This receptor fusion protein (RFP) specifically blocks mOSM signaling, offering new possibilities for anti-cytokine therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Cytokines mediate cellular functions via heteromeric receptor complexes.
- Fusion proteins of receptor subunits show promise as cytokine inhibitors for therapy and research.
Purpose of the Study:
- To construct and evaluate receptor fusion proteins (RFPs) as inhibitors of murine oncostatin M (mOSM).
- To investigate the role of specific domains and subunit arrangement in mOSM-RFP inhibitory activity.
Main Methods:
- Construction of four mOSM-RFPs using ligand-binding domains of mOSMR and mgp130 subunits.
- Comparison of RFPs with different mgp130 domain compositions (D1-D3 vs. D2-D3) and arrangements.
- Assessment of mOSM-induced STAT3 phosphorylation to determine inhibitory efficacy.
Main Results:
- The D1 domain of mgp130 was found to be dispensable for mOSM binding.
- The arrangement of receptor subunits within the RFP is critical for inhibitory activity.
- Optimal inhibition of mOSM-induced STAT3 phosphorylation was achieved when mOSMR was fused before mgp130.
Conclusions:
- A specific mOSM-RFP, comprising D1-D4 of mOSMR and D2-D3 of mgp130, acts as a potent and specific mOSM inhibitor.
- This single-gene encoded mOSM-RFP presents versatile applications in gene delivery for cytokine inhibition, including viral vectors, transgenic animals, and gene therapy.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Tagging and Fusion Proteins
Inhibitors of Viral Protein Synthesis
Receptor Tyrosine Kinases

